Evolution of the Average Target: Alcon Inc.

Evolution of the Target Price: Alcon Inc.

Changes in Analyst Recommendations: Alcon Inc.

4b4f0.BHMfN4ZG1nok0PcATVnJ5PdKquI6sTrlz_2eCx49xp0.UBxWYNYMhDBJlqBpOA36t8MowNtW9Gqv_r_UY3RMkM9pN29cwiOlOVSnmA~46e6c9bb1ad74dfd8e45bfdf79abbcb0
17/08 Deutsche Bank raises TP for Alcon, but shares down Zonebourse
13/08 BNP Paribas Downgrades Alcon to Neutral, Cuts PT MT
13/08 Bernstein Updates Alcon Estimates, Price Target After 'Strong' Commercial Execution in Q2 MT
11/08 Alcon: Q2 story: Innovation is being well received by the end market Alphavalue
25/05 Baptista Research Upgrades Alcon to Buy Rating MT
12/05 Swiss Market Index Closes Higher; SoftwareOne Shares Jump MT
08/05 Bernstein Keeps Alcon at Outperform After Q1 Results; Estimates, Price Target Revised MT
07/05 Needham Trims Price Target on Alcon to $95 From $100, Keeps Buy Rating MT
06/05 Alcon: Results weren't bad; today's correction is a buying opportunity Alphavalue
06/05 Alcon Price Target Declines as AlphaValue/Baader Cuts Estimates on Rising Competition, Expenses MT
06/05 Swiss stocks - Factors to watch on May 6 RE
05/05 Alcon: Investment case hinges on profitability expansion Alphavalue
21/04 RBC Bullish on Alcon's FY26 Growth Outlook; Outperform Maintained MT
19/03 AlphaValue/Baader Europe Upgrades Alcon to Add Rating, Lifts PT MT
16/03 Bernstein: Risk in Alcon's Implantables Business 'Manageable,' Already Priced In MT
10/03 Bernstein Says Alcon Top Pick in European Medtech Coverage, Notes 'Good Momentum' for Key Products into FY26 MT
06/03 Berenberg Keeps Alcon at Buy Amid Signs of US Cataract Market Rebound MT
04/03 Alcon Kept at Outperform as RBC Notes 'Positive Setup' Through FY26; Estimates Revised MT
27/02 Equita SIM Upgrades Alcon to Buy, Raises PT MT
26/02 Needham Raises Price Target on Alcon to $100 From $98, Keeps Buy Rating MT
26/02 Wells Fargo Upgrades Alcon AG to Overweight From Equal Weight, Adjusts PT to $97 From $88 MT
26/02 Alcon Estimates Tweaked as Bernstein Notes Potential Upside from End-market Recovery; Price Target Up MT
25/02 Alcon: Markets forgive Q4 miss for a healthy 2026 outlook Alphavalue
18/02 RBC Updates Alcon Estimates Ahead of FY25 Earnings; Outperform Rating Kept MT
11/02 RBC Expects Alcon's Upcoming FY26 Guidance to Drive Share Price Volatility; Outperform Rating Kept MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+48.45%
+23.1%
+7.58%
+5.32%
+59.21%
+25.37%
+14.04%
+61.73%
+10.81%
Average +28.40%
Weighted average by Cap. +35.20%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
74.25USD
Average target price
91.40USD
Spread / Average Target
+23.10%
High Price Target
105.05USD
Spread / Highest target
+41.47%
Low Price Target
59.24USD
Spread / Lowest Target
-20.21%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BNP Paribas
alphavalue Abhishek Raval
Baptista Research
Needham & Co.
AlphaValue/Baader Europe
Equita SIM
Wells Fargo Securities
Deutsche Bank Securities
Citigroup
Barclays
Kepler Cheuvreux
Deutsche Bank Research
Redburn Atlantic
Ameriprise Advisor Services
RBC Capital Markets
Berenberg Bank
UBS
Oppenheimer
Stifel Nicolaus
Baird
Argus
Mizuho Securities
KeyBanc Capital Markets
Bernstein
Morgan Stanley
Jefferies & Co.
BNP Paribas Exane
Nephron Research
Societe Generale
JPMorgan Chase
BTIG
Credit Suisse
DA Davidson
Stephens Inc.
Goldman Sachs
Exane BNP
Kepler Capital Markets
SVB Leerink
Davy
Octagon Capital
JPMORGAN James Gordon
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
74.25USD
Average target price
91.40USD
Spread / Average Target
+23.10%

Quarterly revenue - Rate of surprise